Endothelin-converting enzyme-1 degrades internalized somatostatin-14


It is advisable to refer to the publisher’s version if you intend to cite from the work.

To link to this article DOI: http://dx.doi.org/10.1210/en.2007-1628

Publisher: Endocrine Society

All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in the End User Agreement.

www.reading.ac.uk/centaur

CentAUR
Central Archive at the University of Reading

Reading's research outputs online
Endothelin-Converting Enzyme-1 Degrades Internalized Somatostatin-14

Dirk Roosterman, Cordula Kempkes, Graeme S. Cottrell, Benjamin E. Padilla, Nigel W. Bunnett, Christoph W. Turck, and Martin Steinhoff

Department of Dermatology (D.R., C.K., M.S.), Interdisziplinäres Zentrum für Klinische Forschung Münster, Ludwig Boltzmann Institute for Cell and Immunobiology of the Skin, University Münster, D-48149 Münster, Germany; Departments of Surgery and Physiology (G.S.C., B.E.P., N.W.B.), University of California, San Francisco, San Francisco, California 94143-0660; and Max Planck Institute of Psychiatry, Proteomics and Biomarkers (C.W.T.), D-80804 Munich, Germany

Agonist-induced internalization of somatostatin receptors (ssts) determines subsequent cellular responsiveness to peptide agonists and influences sst receptor scintigraphy. To investigate sst2A trafficking, rat sst2A tagged with epitope was expressed in human embryonic kidney cells and tracked by antibody labeling. Confocal microscopic analysis revealed that stimulation with sst and octreotide induced internalization of sst2A. Internalized sst2A remained sequestered within early endosomes, and 60 min after stimulation, internalized sst2A still colocalized with the early endosomal antigen-1 (EEA1) and rab5a. Internalized 125I-Tyr1-SST-14 was rapidly hydrolyzed by endosomal endopeptidases, with radioactive metabolites being released from the cell. Internalized 125I-Tyr1-octreotide accumulated as an intact peptide and was released from the cell as an intact peptide ligand. We have identified ECE-1 as one of the endopeptidases responsible for inactivation of internalized SST-14. ECE-1-mediated cleavage of SST-14 was inhibited by the specific ECE-1 inhibitor, SM-19712, and by preventing acidification of endosomes using bafilomycin A1, ECE-1 cleaved SST-14 but not octreotide in an acidic environment. The metallopeptidases angiotensin-1 converting enzyme and ECE-2 did not hydrolyze SST-14 or octreotide. Our results show for the first time that stimulation with SST-14 and octreotide induced sequestration of sst2A into early endosomes and that endocytosed SST-14 is degraded by endopeptidases located in early endosomes. Furthermore, octreotide was not degraded by endosomal peptidases and was released as an intact peptide. This mechanism may explain functional differences between octreotide and SST-14 after sst2A stimulation. Moreover, further investigation of endopeptidase-regulated trafficking of neuropeptides may result in novel concepts of neuropeptide receptor inactivation in cancer diagnosis. (Endocrinology 149: 2200–2207, 2008)
the calcitonin gene-related peptide (CGRP) (CRL) (11). ECE-1 is a metalloendopeptidase related to nephrilysin (12). Its four isoforms (ECE-1a–d) share a catalytic domain, but differences in the cytosolic tail determine their subcellular location (13–15). All four isoforms are present within vesicles inside the cell, and ECE-1a as well as ECE-1c are also present at the plasma membrane. We observed that ECE-1 degrades and inactivates SP and CGRP. Endosomal degradation of ligands by ECE-1 allowed recycling and resensitization of the receptors. These experiments identified a new role for ECE-1 in regulating receptor trafficking.

Recent studies of sst2A have shown that the β-arrestin-dependent trafficking of the sst2A sst receptor resembled that of a “class B” receptor (6). Furthermore, investigation of sst2A-mediated uptake of 125I-SST-14 did not clearly show if dependent trafficking of the sst2A sst receptor resembled or octreotide induced internalization of sst2A and sequestration of the endocytosed peptides are unknown. We found that stimulation of sst2A with SST-14 for 60 min. The supernatants were collected, acidified by adding 50 mg/ml G418 (Invitrogen).

The aim of the present study was to characterize the fate of endocytosed sst2A and its associated ligands SST-14 and octreotide. We found that stimulation of sst2A with SST-14 or octreotide induced internalization of sst2A and sequestration of the receptor within early endosomes. Internalized 125I-Tyr1-SST-14 is degraded by endosomally located peptidases. Interestingly, inhibition of the activity of the endosomally located peptidases ECE-1 with SM-19712 or preventing acidification of endosomes using bafilomycin A1 only partially inhibits degradation of SST-14, indicating that other peptidases participate in the degradation of internalized SST-14. Two iodinated metabolites of SST-14 accumulated within the cell during stimulation, whereas mainly one peptide metabolite was detected in the supernatant. Internalized 125I-Tyr1-SST-14 was not routed to lysosomes for degradation. Interestingly, octreotide accumulated as an intact peptide in the cells and was slowly released as an intact peptide from the cells. Further investigation of the metalloendopeptidases mediating degradation of sst showed that SST-14 was not degraded at acidic pH or neutral pH by recombinant human (rh) ECE-2 and rh angiotensin-1 converting enzyme (ACE-1), whereas ECE-1 just degraded SST-14 at an acidic pH. In contrast, octreotide was not degraded by rhECE-1, rhECE-2, or rhACE.

**Materials and Methods**

**Materials**

SST-14 and octreotide were from Bachem (Torrance, CA). 125I-Tyr1-SST-14 was from Amersham Biosciences (Braunschweig, Germany), and 125I-Tyr1-octreotide was from Anawa (Cologne, Germany). Mouse antipeptide in the cells and was slowly released as an intact peptide or as a metabolite of 125I-SST-14 (5). Therefore, the effects of the natural agonist SST-14 and the peptidase-resistant and clinically useful agonist octreotide on the subcellular localization of sst2A have not been fully evaluated, and the fate of the endocytosed peptides are unknown.

The aim of the present study was to characterize the fate of endocytosed sst2A and its associated ligands SST-14 and octreotide. We found that stimulation of sst2A with SST-14 or octreotide induced internalization of sst2A and sequestration of the receptor within early endosomes. Internalized 125I-Tyr1-SST-14 is degraded by endosomally located peptidases. Interestingly, inhibition of the activity of the endosomally located peptidases ECE-1 with SM-19712 or preventing acidification of endosomes using bafilomycin A1 only partially inhibits degradation of SST-14, indicating that other peptidases participate in the degradation of internalized SST-14. Two iodinated metabolites of SST-14 accumulated within the cell during stimulation, whereas mainly one peptide metabolite was detected in the supernatant. Internalized 125I-Tyr1-SST-14 was not routed to lysosomes for degradation. Interestingly, octreotide accumulated as an intact peptide in the cells and was slowly released as an intact peptide from the cells. Further investigation of the metalloendopeptidases mediating degradation of sst showed that SST-14 was not degraded at acidic pH or neutral pH by recombinant human (rh) ECE-2 and rh angiotensin-1 converting enzyme (ACE-1), whereas ECE-1 just degraded SST-14 at an acidic pH. In contrast, octreotide was not degraded by rhECE-1, rhECE-2, or rhACE.

**Materials and Methods**

**Materials**

SST-14 and octreotide were from Bachem (Torrance, CA). 125I-Tyr1-SST-14 was from Amersham Biosciences (Braunschweig, Germany), and 125I-Tyr1-octreotide was from Anawa (Cologne, Germany). Mouse antipeptide in the cells and was slowly released as an intact peptide or as a metabolite of 125I-SST-14 (5). Therefore, the effects of the natural agonist SST-14 and the peptidase-resistant and clinically useful agonist octreotide on the subcellular localization of sst2A have not been fully evaluated, and the fate of the endocytosed peptides are unknown.

The aim of the present study was to characterize the fate of endocytosed sst2A and its associated ligands SST-14 and octreotide. We found that stimulation of sst2A with SST-14 or octreotide induced internalization of sst2A and sequestration of the receptor within early endosomes. Internalized 125I-Tyr1-SST-14 is degraded by endosomally located peptidases. Interestingly, inhibition of the activity of the endosomally located peptidases ECE-1 with SM-19712 or preventing acidification of endosomes using bafilomycin A1 only partially inhibits degradation of SST-14, indicating that other peptidases participate in the degradation of internalized SST-14. Two iodinated metabolites of SST-14 accumulated within the cell during stimulation, whereas mainly one peptide metabolite was detected in the supernatant. Internalized 125I-Tyr1-SST-14 was not routed to lysosomes for degradation. Interestingly, octreotide accumulated as an intact peptide in the cells and was slowly released as an intact peptide from the cells. Further investigation of the metalloendopeptidases mediating degradation of sst showed that SST-14 was not degraded at acidic pH or neutral pH by recombinant human (rh) ECE-2 and rh angiotensin-1 converting enzyme (ACE-1), whereas ECE-1 just degraded SST-14 at an acidic pH. In contrast, octreotide was not degraded by rhECE-1, rhECE-2, or rhACE.

**Materials and Methods**

**Materials**

SST-14 and octreotide were from Bachem (Torrance, CA). 125I-Tyr1-SST-14 was from Amersham Biosciences (Braunschweig, Germany), and 125I-Tyr1-octreotide was from Anawa (Cologne, Germany). Mouse antipeptide in the cells and was slowly released as an intact peptide or as a metabolite of 125I-SST-14 (5). Therefore, the effects of the natural agonist SST-14 and the peptidase-resistant and clinically useful agonist octreotide on the subcellular localization of sst2A have not been fully evaluated, and the fate of the endocytosed peptides are unknown.

The aim of the present study was to characterize the fate of endocytosed sst2A and its associated ligands SST-14 and octreotide. We found that stimulation of sst2A with SST-14 or octreotide induced internalization of sst2A and sequestration of the receptor within early endosomes. Internalized 125I-Tyr1-SST-14 is degraded by endosomally located peptidases. Interestingly, inhibition of the activity of the endosomally located peptidases ECE-1 with SM-19712 or preventing acidification of endosomes using bafilomycin A1 only partially inhibits degradation of SST-14, indicating that other peptidases participate in the degradation of internalized SST-14. Two iodinated metabolites of SST-14 accumulated within the cell during stimulation, whereas mainly one peptide metabolite was detected in the supernatant. Internalized 125I-Tyr1-SST-14 was not routed to lysosomes for degradation. Interestingly, octreotide accumulated as an intact peptide in the cells and was slowly released as an intact peptide from the cells. Further investigation of the metalloendopeptidases mediating degradation of sst showed that SST-14 was not degraded at acidic pH or neutral pH by recombinant human (rh) ECE-2 and rh angiotensin-1 converting enzyme (ACE-1), whereas ECE-1 just degraded SST-14 at an acidic pH. In contrast, octreotide was not degraded by rhECE-1, rhECE-2, or rhACE.

**Materials and Methods**

**Materials**

SST-14 and octreotide were from Bachem (Torrance, CA). 125I-Tyr1-SST-14 was from Amersham Biosciences (Braunschweig, Germany), and 125I-Tyr1-octreotide was from Anawa (Cologne, Germany). Mouse antipeptide in the cells and was slowly released as an intact peptide or as a metabolite of 125I-SST-14 (5). Therefore, the effects of the natural agonist SST-14 and the peptidase-resistant and clinically useful agonist octreotide on the subcellular localization of sst2A have not been fully evaluated, and the fate of the endocytosed peptides are unknown.

The aim of the present study was to characterize the fate of endocytosed sst2A and its associated ligands SST-14 and octreotide. We found that stimulation of sst2A with SST-14 or octreotide induced internalization of sst2A and sequestration of the receptor within early endosomes. Internalized 125I-Tyr1-SST-14 is degraded by endosomally located peptidases. Interestingly, inhibition of the activity of the endosomally located peptidases ECE-1 with SM-19712 or preventing acidification of endosomes using bafilomycin A1 only partially inhibits degradation of SST-14, indicating that other peptidases participate in the degradation of internalized SST-14. Two iodinated metabolites of SST-14 accumulated within the cell during stimulation, whereas mainly one peptide metabolite was detected in the supernatant. Internalized 125I-Tyr1-SST-14 was not routed to lysosomes for degradation. Interestingly, octreotide accumulated as an intact peptide in the cells and was slowly released as an intact peptide from the cells. Further investigation of the metalloendopeptidases mediating degradation of sst showed that SST-14 was not degraded at acidic pH or neutral pH by recombinant human (rh) ECE-2 and rh angiotensin-1 converting enzyme (ACE-1), whereas ECE-1 just degraded SST-14 at an acidic pH. In contrast, octreotide was not degraded by rhECE-1, rhECE-2, or rhACE.
were stopped by boiling for 3 min. Reaction products were separated by reversed-phase HPLC using a C-18 column equilibrated in 0.1% TFA in water, and eluted using a linear gradient of 0.1% TFA in acetonitrile (0–40% acetonitrile, 25 min) at 1 ml/min. Peptides were detected by spectrophotometry (A256 nm). Products were collected and analyzed by time-of-flight mass spectrometry.

Results

Agonists of sst2A induce receptor internalization and association with β-arrestin1

“Class B” receptors form stable and high-affinity interactions with β-arrestin1 and β-arrestin2 at the cell surface and in endosomes (7, 22). To further characterize the internalization of rat somatostatin receptor 2A (rsst2A), we examined the colocalization of β-arrestin1 with internalized rsst2A. A fusion protein of β-arrestin1 and EGFP (β-arrestin1-EGFP) and T7-rsst2A were transiently coexpressed in HEK293 cells (23). In unstimulated cells, β-arrestin1-EGFP was evenly distributed in the cytoplasm and nucleus (Fig. 1). Stimulation with SST-14 or octreotide for 10 min induced translocation of β-arrestin1-EGFP from the cytosol to the cell membrane, where it colocalized with sst2A. At later times SST-14 and octreotide induced endocytosis of sst2A and β-arrestin1-EGFP to small vesicles close to the cell membrane. The distribution and size of the vesicles are similar to those found in studies analyzing sst2A-mediated internalization of fluorescent SST-14 (24). Internalized sst2A then translocated to hollow core vesicles that also contained β-arrestin1-EGFP (Fig. 1, A and B, arrowheads). Interestingly, in cells stimulated with SST-14, β-arrestin1 is associated with internalized rsst2A (Fig. 1, A and B, arrowheads) and at the cell membrane (Fig. 1, A and B, arrows). In cells stimulated with octreotide, β-arrestin1 is mainly associated with internalized rsst2A. The fluorescence intensity scan (Fig. 1, A and B, yellow arrows) of the cells is shown in Fig. 1, E and F. The fluorescence signal of β-arrestin1-EGFP is more intensified at the plasma membrane in cells stimulated with SST-14 (Fig. 1, E and F, green arrows) than in cells stimulated with octreotide. Thus, stimulation of rsst2A with agonist results in translocation of β-arrestin1 to the plasma membrane and subsequent association with rsst2A for prolonged periods indicative of a “class B” GPCR.
Internalized rsst2A is sequestrated in early endosomes

After stimulation with agonist, “class B” GPCRs such as NK1R, CLR, and angiotensin II type 1A receptor are sequestered within early endosomes for prolonged periods (9, 25, 26). To determine the subcellular location of internalized rsst2A, HEK293 cells were transiently transfected with T7-rsst2A and a marker protein for early endosomes, rab5a-EGFP, and their localization was examined using immunofluorescence and confocal microscopy. In unstimulated cells, rsst2A was present at the plasma membrane, and rab5a was present in vesicles within the cell (data not shown). After stimulation with SST-14 (10 nm, 10 min) and incubation in SST-14-free medium for 60 min, internalized rsst2A colocalized with rab5a-EGFP in small and hollow core vesicles (Fig. 1C, arrowheads). Thus, after stimulation with SST-14, rsst2A traffics to early endosomes and remained there for at least 60 min after stimulation.

Internalized rsst2A colocalizes with endogenous ECE-1

HEK293 cells endogenously express all four isoforms of ECE-1 (10). Within the acidic environment of early endosomes, ECE-1 has inactivated the peptide ligands of some “class B” GPCRs (10, 11). We have previously demonstrated that SP and CGRP are inactivated by ECE-1 endogenously expressed by HEK293 cells. HEK293 cells were transiently transfected with rsst2A and the receptor and ECE-1 localized by immunofluorescence and confocal microscopy. In unstimulated cells, rsst2A was localized at the plasma membrane, and ECE-1 was distributed in cytoplasmic vesicles. After stimulation rsst2A was localized at the plasma membrane and colocalized with ECE-1 in vesicles. Thus, rsst2A is transported from the plasma membrane to early endosomes where it remains colocalized with ECE-1 (Fig. 1D).

Recovery of agonist-binding sites after sst2A stimulation

Another characteristic of “class B” GPCRs is that they slowly recycle back to the cell surface because they were sequestered within early endosomes. Confocal microscopical analysis of rsst2A expressed in rat insulinoma cell line 1046–38 or in HEK293 cells suggests that rsst2A recycled to the plasma membrane within 1–2 h (6, 18). Therefore, we analyzed rsst2A recycling by determining the reappearance of cell surface binding sites after stimulation with SST-14 or octreotide. Rat rsst2A-HEK293 cells were stimulated with SST-14 or octreotide, and the recovery of surface binding sites was determined by incubation with 125I-SST-14. We found that stimulation with SST-14 or octreotide rapidly induced a marked reduction of surface binding sites (Fig. 2). After stimulation (10 min, 37 C), surface binding sites of SST-14 (51 ± 3%) and octreotide (45 ± 4%) were markedly reduced. Interestingly, the binding sites did not recover during 2-h incubation at 37 C. These findings indicate that rsst2A remained internalized for at least 2 h after stimulation with both peptide ligands. This slow recovery of binding sites is indicative of the classical trafficking of a class B GPCR.

Internalized 125I-Tyr11-SST-14 but not 125I-Tyr1-octreotide is degraded by endosomal endopeptidases

Because the receptor-ligand complex of “class B” receptors is sequestered within acidic early endosomes, endosomal located peptidases are capable of mediating the degradation of the endocytosed peptide ligands (10, 11). We analyzed the degradation of 125I-SST-14 and 125I-octreotide in HEK293 cells stably expressing sst2A. Cells were incubated for 0–15 min with 100,000 cpm radiolabeled peptide, mixed with 1 nm unlabeled peptide in HBSS (0.1% BSA) at 37 C, washed twice with acidic HBSS (pH 4.8), and once with HBSS (0.1% BSA), and incubated for 0–90 min at 37 C. Cell lysates and supernatants were collected and analyzed by HPLC. Analysis of cell lysates from SST-14-treated cells indicates that SST-14 was rapidly endocytosed by rsst2A-HEK293 cells (Fig. 3A, closed diamonds). SST-14 was rapidly degraded into two radioactive labeled peptide metabolites that accumulated within the cell. After 15-min incubation with 125I-SST-14, only 42.9% of total radioactivity was found to be cell associated as intact 125I-SST-14. Of the remaining radioactivity, 19.3% was peptide A (retention time, 9 min), and 37.7% was peptide B (retention time, 11 min) (Fig. 3A). Incubation for longer periods at 37 C induced further degradation of the internalized SST-14. At 90 min after stimulation, only 7.3% of the total radioactivity remained as intact SST-14, whereas 13.7% of the total radioactivity was peptide B, and 2.6% of the total radioactivity was peptide A. Interestingly, most of the radioactivity was released from the cells (Fig. 3C). HPLC analysis of supernatants demonstrated that two peptide metabolites were released from the cells. The major product was peptide B (69.2% of the total radioactivity), with the minor product, peptide A, only being 4.9% of the total radioactivity. The small amount of peptide A detected in the supernatant (4.9%, even after 90 min) is in marked contrast to the maximal amount associated with the cell after 15 min (19.3% of total radioactivity). These findings suggest that peptide A is an intermediate degradation product before being further processed to peptide B.

We found that incubation of rsst2A cells with 125I-octreotide
induced accumulation of intact octreotide in the cells (Fig. 3B). Ninety minutes after cells were washed, 83% of the internalized octreotide was still cell associated, and 17% of the radioactivity was found in the supernatant as intact octreotide (Fig. 3D).

As shown in a representative HPLC chromatogram (Fig. 3E), intact radiolabeled SST-14 eluted by 16 min, and two radioactive degradation products accumulated in the cells (closed triangles and closed circles) during the incubation with 125I-SST-14. C, The degradation products were rapidly released from the cells. Intact 125I-SST-14 was not detected in the supernatant. The degradation product with the retention time of 11 min was the major degradation product detected in the supernatant. B, During incubation of cells, octreotide accumulated as an intact peptide within the cell. No degradation products were detected as cell associated. After washing, the amount of cell-associated octreotide decreased to 83%. D, Only intact octreotide was detected in the supernatant. No degradation products of octreotide were detected in the supernatant. E, A representative HPLC profile of cell-associated 125I-SST-14 after 5-min incubation with 125I-SST-14. F, The influence of the ECE-1 inhibitor SM-19712 and bafilomycin A on the degradation of 125I-SST-14. Cells were pretreated with SM-19712 (10 μM) or bafilomycin A (1 μM) for 30 min, stimulated with 125I-SST-14 for 15 min, washed, and incubated for 60 min in the presence of the inhibitors. In control cells, 7.3% of the total radioactivity was intact SST-14. In cells pretreated with SM-19712, 24% of the total radioactivity was intact SST-14. In cells pretreated with bafilomycin A, 26% of the total radioactivity was intact SST-14, **, P < 0.01 to control. G, The sequences of SST-14 and octreotide. The peptides were digested with rhECE-1, and the products were purified by HPLC and identified by mass spectrometry.

As shown in a representative HPLC chromatogram (Fig. 3E), intact 125I-Tyr11-SST-14 eluted by 16 min, and two radioactive degradation products (peptide A and peptide B) were recognized by HPLC as having eluted by 9 and 11 min, respectively. The 25Tyr eluted by 3–4 min and could not be detected in the cell lysate or the supernatant of rsst2A-HEK cells, indicating that SST-14 was not routed to lysosomal degradation (11).

HEK293 cells endogenously express all four isoforms of ECE-1 (10). Therefore, in our next set of experiments, we tried to inhibit intracellular degradation of internalized 125I-SST-14 by preincubating the cells with the ECE-1-specific inhibitor, SM-19712 (10 μM), and by neutralizing acidic vesicles by preincubating with bafilomycin A1 (1 μM). Both inhibitors had been previously tested for the ECE-1-mediated degradation of internalized SP and CGRP (10, 11). We preincubated cells for 15 min with 100,000 cpm 125I-Tyr11-SST-14 mixed with 1 nM SST-14 in the presence of the inhibitors, washed, and incubated for 60 min at 37 C. Without inhibitor, 7.3% (4) of the total radioactivity was intact 125I-Tyr11-SST-14. In cells pretreated with SM-19712, 24% of the total radioactivity was intact 125I-Tyr11-SST-14. In cells pretreated with bafilomycin A1, 26 ± 4% was intact 125I-Tyr11-SST-14 (Fig. 3F). These findings indicate that SM-19712 significantly blocked the intracellular degradation of 125I-Tyr11-SST-14 and that the degradation is sensitive to neutralization of acidic vesicles. Interestingly, whereas the intracellular degradation of SP or CGRP could be almost completely blocked with SM-19712 and bafilomycin A1 (10, 11), the degradation of 125I-Tyr11-SST-14 was only partially blocked with the inhibitors, indicating that besides ECE-1,
other endopeptidases participate in the endosomal degradation of SST-14. Figure 3G shows the sequences of SST-14 and octreotide. The arrows mark the sites of cleavage by ECE-1 inferred from the product masses.

We next sought to determine whether other endopeptidases were able to degrade SST-14. Therefore, we tested rhECE-1, rhECE-2, and rhACE-1 to see if they degraded SST-14 and octreotide. The activity of the metallopeptidases was measured with the synthetic fluorescence substrate McaBK2. We tested the degradation of McaBK2 at neutral pH and at pH 5.8, which is equal to the pH of acidic early endosomes (10). The metallopeptidases are active at pH 5.8 (data not shown). At neutral pH, rhACE degrades McaBK2 10 times faster than at pH 5.5, whereas rhECE-2 did not degrade McaBK2 at pH 7.4 (data not shown). While testing the degradation of SST-14 and octreotide, we found that ECE-1 did not degrade octreotide in an acidic environment but did degrade SST-14 (Fig. 4, A and B). Time-of-flight mass spectroscopy showed that SST-14 was degraded at position Asn\(^{5}\)-Phe\(^{6}\) and at position Thr\(^{10}\)-Phe\(^{11}\), leading to two degradation products: the peptide SST-14 (1–5)–SST-14 (11–14) and to SST-14 (6–10).

Figure 4C shows the time course of rhECE-1 mediated degradation of SST-14 in an acidic and neutral environment. At pH 5.8, rhECE-1 rapidly degraded SST-14. After 30-min incubation, 50% of the SST-14 was degraded. Interestingly, prolonged incubation with rhECE-1 did not result in a complete degradation of the peptide. A similar incomplete degradation profile was observed for the ECE-1 mediated degradation of CGRP (11).

Figure 4D shows the amount of intact peptide for octreotide and SST-14 after 90-min incubation with rhACE, rhECE-2, and rhECE-1. Of note, octreotide was not degraded by any of these endopeptidases. SST-14 was only degraded by ECE-1 in an acidic environment by approximately 50% (Fig. 4D). None of the other tested endopeptidases hydrolyzed SST-14.

Discussion

The first aim of this investigation was to determine the subcellular localization of internalized sst2A. Our results show that stimulation with SST-14 or octreotide induced internalization of sst2A into early endosomes. Even 60 min after stimulation, sst2A still colocalized with the early endosomal marker protein rab5a. These results, including the strong association of internalized rsst2A with β-arrestin1-EGFP, indicate that sst2A trafficking resembles the trafficking mechanism of a “class B” receptor (9, 26). Interestingly, β-arrestin1 is located at the cell membrane and at early endosomes when the cells are stimulated with SST-14, whereas β-arrestin1 is mainly associated with early endosomes after stimulation with octreotide. The data let us suggest that degradation of SST-14 allowed dissociation of β-arrestin1 from internalized rsst2A and translocation of β-arrestin1 to the cell membrane. Our results are in line with previous results analyzing β-arrestin trafficking and endosomal sorting of other sst receptors subtypes (6, 18). Interestingly, whereas confocal analysis of the recycling behavior of sst2A in rat insulinoma 1046–38 cells or HEK293 suggests that sst2A recycled within 1–2 h, we were unable to observe recycling of rsst2A 60 min after stimulation. That we were able to determine the reappearance of surface binding sites indicates that sst2A did not recycle 2 h after stimulation with the cognitive ligand.

Another characteristic of “class B” GPCRs is the formation of hollow core vesicles. This has been clearly demonstrated for the AT(1A)R and the NK1R (9, 26). Hollow core vesicles are enlarged vesicles, which are formed by the constitutively active rab5a mutant rab5aQ79L. Other studies found that rab5a is a binding protein of the AT(1A)R and suggested that

Fig. 4. Degradation of SST-14 and octreotide with rhACE, rhECE-2, and rhECE-1. A, The HPLC profile of octreotide (250 μM) incubated with ECE-1 (0.5 μg) for 90 min at 37 C (pH 5.8). Octreotide was not degraded by ECE-1. B, The HPLC profile of SST-14 incubated with ECE-1 for 90 min at 37 C (pH 5.8). C, The time dependence of ECE-1-mediated degradation of SST-14 at pH 5.8 and pH 7.4. At neutral pH, ECE-1 did not degrade SST-14. SST-14 was rapidly degraded by ECE-1 at pH 5.8. After 30-min incubation, 47% of SST-14 was degraded. Longer incubation of the peptide with ECE-1 did not result in further degradation of the peptide. D, The degradation of octreotide and SST-14 by rhACE, rhECE-2, and rhECE-1 at a neutral pH (gray bars) and at pH 5.8 (black bars). Only SST-14 was degraded by ECE-1 in an acidic environment.
an intrinsic guanosine 5’-diphosphate-guanosine 5’-triphosphate (GTP) exchange element is encoded in the carboxy-terminal tail of the AT(1A)R (25, 26). The direct interaction of phosphorylated receptor and activated (GTP-bound) rab5a may lead to the homotypic fusion of early endosomes and the subsequent formation of hollow core vesicles. A detailed analysis of deletion mutants of AT(1A)R demonstrated that truncation of the C-terminal tail of the receptor inhibits the formation of hollow core vesicles but does not inhibit internalization of the receptor (26). Previous studies showing that the guanosine 5’-diphosphate-GTP-exchange element is coded at the far end of the C terminus of the AT(1A)R let us suggest that the naturally occurring splice variant of sst2, sst2B, demonstrates a different pattern of internalization, resensitization, and trafficking compared with sst2A (27, 28).

Our confocal microscopic observation of T7-rsst2A and β-arrestin1-EGFP also shows that stimulation with SST-14 and octreotide induced the formation of β-arrestin1 and coated hollow core vesicles. These results indicate that rss2A trafficking is blocked in early endosomes. The localization within early endosomes could be also demonstrated by the colocalization of internalized rss2A with rab5a-EGFP. Because the receptor is not immediately transported to late endosomes, and the ligand is not routed into lysosomal degradation, endopeptidases with an acidic pH optimum for degradation of small peptides, like ECE-1 or ECE-2, should be involved in the hydrolysis and inactivation process of the endocytosed peptide ligands (29, 30). Recently, the endopeptidase ACE was also cotransported with internalized receptors (31), suggesting that this degrading enzyme may not necessarily be constitutively located within early endosomes. The degradation of an internalized peptide agonist by early endosomally located endopeptidases was recently demonstrated for the NK1R/SP and for the CLR/CGRP system (10, 11). The same studies showed that for both class B receptors, intracellular ECE-1 inactivates the internalized ligand within early endosomes and allowed dissociation of β-arrestin1 from the internalized receptor. They also showed that the degradation of ligand by ECE-1 is an essential step in the process of neupeptide receptor trafficking and resensitization. In particular, ECE-1 cleaved SP at positions Gln6–Phe7 and Gly9–Leu10 to form the metabolites SP[1–6] and SP[1–9]. Similar to the degradation of SP and CGRP, that of SST-14 by ECE-1 is also sensitive to a specific pH. In the present study, we compared the fate of a natural ligand, SST-14, and the long-lasting synthetic sst analog octreotide in cells expressing rss2A. Both peptides induced internalization and sequestration of sst2A within early en-
dosomes. In early endosomes, SST-14 was hydrolyzed and inactivated by different endopeptidases. The endopeptidase-generated degradation products were released as peptide fragments from these cells. At the same time, the internalized receptor remained intracellularly located and was not recycled. Furthermore, the synthetic analog (octreotide) remained as an intact ligand for a prolonged time within the cells, where it colocalized with the internalized receptor sst2A. The finding that an internalized ligand of sst2A can be degraded within early endosomes while not routed into lysosomal degradation will help to develop novel radiolabeled sst or other neuropeptide ligand analogs useful for medical diagnostics such as tumor imaging as well as molecular imaging for in vivo models of inflammation (33, 34).

Acknowledgments

We thank Dr. H.-J. Kreienkamp for the kind gift of T7-somatostatin receptor 2A cDNA.

Received November 28, 2007. Accepted January 24, 2008.

Address all correspondence and requests for reprints to: Dr. Dirk Roosterman, Department of Dermatology, Interdisziplinäres Zentrum für Klinische Forschung Münster, and Ludwig Boltzmann Institute for Cell and Immunobiology of the Skin, University Münster, D-48149 Münster, Germany. E-mail: roosterman@gmx.net.

This work was supported by grants from Interdisziplinäres Zentrum für Klinische Forschung Münster (STEI2/076/06), SFB 293 (A14), and Ludwig Boltzmann Institute for Cell and Immunobiology of the Skin, University Münster, D-48149 Münster, Germany. E-mail: roosterman@gmx.net.

Disclosure Statement: The authors have nothing to declare.

References


24. Dabert L, Beaudet JL, Rab9b AV, Ferguson SS. 2004 Regulation of angio tensin II type 1A receptor intracellular retention, degradation, and recycling by Rab9b, Rab7, and Rab11 GTPases. J Biol Chem 279:13110–13118


Endocrinology is published monthly by The Endocrine Society (http://www.endo-society.org), the foremost professional society serving the endocrine community.